AI-aided protein design requires massive amounts of data to train the models on. The field of antibody development has struggled to provide the high-quality biological data that is needed for good AI models to generate results: “Drug discovery has a biological data problem,” says CEO McClain. Absci has been collecting antibody data over the past decade, which has allowed the company to build its zero-shot generative AI method.
The happy marriage of synthetic biology and AI that has enabled creating new antibodies with the exact specifications you want was made possible thanks to another unlikely hero in this story. An important piece of the technology that positioned Absci for success was figuring out how to manufacture antibodies in, the model organism of synthetic biology. Traditionally, antibodies are made in mammalian cells, which are slower to grow and harder to manipulate.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
More women are using VR headsets for workouts, one company saysInsider tells the global tech, finance, markets, media, healthcare, and strategy stories you want to know.
ソース: BusinessInsider - 🏆 729. / 51 続きを読む »